Compare Kyndryl Holdings Inc (KD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Moderna, Inc. — how do they compare? Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B), while Moderna, Inc. trades at $59.66 (market cap $23.60B). The key difference: Moderna, Inc. is far larger — about 8.8× Kyndryl Holdings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | MRNA | |
|---|---|---|
Market Cap | $2.69B | $23.60B |
Sector | Technology | Health |
52-Week High | $39.47 | $81.80 |
52-Week Low | $10.59 | $22.36 |
Enterprise Value | $5.03B | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KD trades at $12.19, up 0.33% on the day, with a neutral technical signal. The company reported revenue of $15.06B in 2025, with net income turning positive to $252M after three years of losses. Recent news includes a partnership with Microsoft for sovereignty solutions and ongoing legal investigations into officers and directors.
The outlook is mixed; improving profitability and a low P/E of 14.38 suggest value, but recent earnings misses and legal scrutiny pose risks. Analyst consensus is a $14.00 price target with a hold rating, indicating cautious optimism amid transformation efforts.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
